

## OTHER PUBLICATIONS FROM

# THE COPENHAGEN GENERAL POPULATION STUDY (Herlev/Østerbroundersøgelsen)

### 2009

1. Nordestgaard BG, Lytken Larsen M. Hyperlipidæmi. Kapitel 30. **Medicinsk Kompendium**, 17. udgave. Nyt Nordisk Forlag Arnold Busck. København 2009; side 865-894.
2. Nordestgaard BG, Langsted a, Freiberg JJ. Nonfasting hyperlipidemia and cardiovascular disease. **Curr Drug Targets** 2009;10:328-35.
3. Zacho J, Tybjærg-Hansen A, Jensen JS, Grande P, Sillesen H, Nordestgaard BG. C-reactive protein and risk of ischaemic vascular and cerebrovascular disease--secondary publication. **Ugeskr Laeger** 2009;171:1751-5.
4. Zacho J, Tybjærg-Hansen A, Nordestgaard BG. C-reactive protein, genetically elevated levels and risk of ischemic heart and cerebrovascular disease. **Scand J Clin Lab Invest** 2009;69:442-6.
5. Langsted A, Freiberg JJ, Nordestgaard BG. Fasting and nonfasting lipids--secondary publication. **Ugeskr Laeger** 2009;171:2184-7.
6. Nordestgaard BG. Does elevated C-reactive protein cause human atherothrombosis? Novel insights from genetics, intervention trials, and elsewhere. **Curr Opin Lipidol** 2009; 20: 393-401.
7. Nordestgaard BG, Zacho J. Lipids, atherosclerosis and CVD risk: is CRP an innocent bystander? **Nutr Metab Cardiovasc Dis** 2009;19:521-4.
8. Nordestgaard BG. Does elevated C-reactive protein cause human atherothrombosis? Novel insights from genetics, intervention trials, and elsewhere. **Curr Opin Lipid** 2009; 20: 393-401.
9. Nordestgaard BG, Zacho J. Lipids, atherosclerosis and CVD risk: is CRP an innocent bystander? **Nutr Metab Cardiovasc Dis** 2009; 19: 521-524.
10. Kamstrup PR, Nordestgaard BG. Lipoprotein(a) should be taken much more serious. **Biomarkers Med** 2009; 3:439-441.

### 2010

11. Frikke-Schmidt R. Genetic variation in the ABCA1 gene, HDL cholesterol, and risk of ischemic heart disease in the general population. **Atherosclerosis** 2010; 208: 305-316.
12. Nordestgaard BG. The Finnish success of cardiovascular risk factor reduction. **Int J Epidemiol** 2010; 39: 518-519.
13. Nordestgaard BG, Chapman MJ, Ray K, Borén J, Andreotti F, Watts GF, Ginsberg H, Amarenco P, Catapano A, Descamps OS, Fisher E, Kovanen P, Kuivenhoven JA, Lesnik P, Masana L, Reiner Z, Taskinen MR, Tokgözoğlu L, Tybjærg-Hansen A. European Atherosclerosis Society Consensus Panel. Lipoprotein(a) as a Cardiovascular Risk Factor: Current Status. **Eur Heart J** 2010; 31: 2844-2853.

### 2011

14. Kamstrup PR, Tybjærg-Hansen A, Nordestgaard BG. Lipoprotein(a) and risk of myocardial infarction - genetic epidemiologic evidence of causality. **Scand J Clin Lab Invest** 2011; 71: 87-93.

15. Nordestgaard BG, Tybjaerg-Hansen A. Genetic determinants of LDL, lipoprotein(a), triglyceride-rich lipoproteins and HDL: concordance and discordance with cardiovascular disease risk. **Curr Opin Lipid** 2011; 22: 113-122.
16. Nordestgaard BG, Freiberg JJ. Clinical relevance of non-fasting and postprandial hypertriglyceridemia and remnant cholesterol. **Curr Vasc Pharmacol** 2011; 9: 281-286.
17. Kolovou G, Mikhailidis DP, Nordestgaard BG, Bilianou H, Panotopoulos G. Definition of postprandial lipemia. **Curr Vasc Pharmacol** 2011; 9: 292-301.
18. Ooi TC, Nordestgaard BG. Methods To Study Postprandial Lipemia. **Curr Vasc Pharmacol** 2011; 9: 302-308.
19. Kolovou GD, Mikhailidis DP, Kovar J, Lairon D, Nordestgaard BG, Ooi TC, Perez-Martinez P, Bilianou H, Anagnostopoulou KK, Panotopoulos G. Assessment and clinical relevance of non-fasting and postprandial triglycerides: an expert panel statement. **Curr Vasc Pharmacol** 2011; 9: 258-270.
20. Chapman MJ, Ginsberg HN, Amarenco P, Andreotti F, Borén J, Catapano AL, Descamps OS, Fisher E, Kovanen PT, Kuivenhoven JA, Lesnik P, Masana L, Nordestgaard BG, Ray KK, Reiner Z, Taskinen MR, Tokgözoğlu L, Tybjaerg-Hansen A, Watts GF; European Atherosclerosis Society Consensus Panel. The European Atherosclerosis Society Consensus Panel. Triglyceride-Rich Lipoproteins and High-Density Lipoprotein Cholesterol in Patients at High Risk of Cardiovascular Disease: Evidence and Guidance for Management. **Eur Heart J** 2011; 32: 1345-1361.
21. Silverman EK, Vestbo J, Agusti A, Anderson W, Bakke PS, Barnes KC, Graham Barr R, Bleecker ER, Marike Boezen H, Burkart KM, Celli BR, Cho MH, Cookson WO, Croxton T, Daley D, Demeo DL, Gan W, Garcia-Aymerich J, Hall IP, Hansel NN, Hersh CP, Kalsheker N, Kiley JP, Jin Kim W, Lambrechts D, Lee SD, Litonjua AA, Lomas DA, London SJ, Nishimura M, Nordestgaard BG, O'Donnell CJ, Postma DS, Puhon MA, Tesfaygi Y, Tobin MD, Vogelmeier C, Wilk JB, Wouters E, Young RP, Ziegler-Heitbrock L, MacNee W, Crapo JD. Opportunities and Challenges in the Genetics of COPD 2010: An International COPD Genetics Conference Report. **COPD** 2011;8:121-135.
22. Allin KH, Nordestgaard BG. Elevated C-reactive protein in the diagnosis, prognosis, and cause of cancer. **Crit Rev Clin Lab Sci** 2011;48:155-170.

## 2012

23. Kaur-Knudsen D, Bojesen SE, Nordestgaard BG. Cytochrome P450 and 1B1 and 2C9 Genotypes and Risk of Ischemic Vascular Disease, Cancer, and Chronic Obstructive Pulmonary Disease. **Curr Vasc Pharmacol** 2012; 10: 512-520.
24. Nordestgaard BG, Chapman MJ, Ginsberg H. Lipoprotein(a): EAS recommendations for screening, desirable levels and management. **Book** 2012 48 pages.

## 2013

25. Juhasz P, Lynch M, Paniagua M, Campbell J, Adourian A, Guo Y, Li X, Nordestgaard BG, Gordon N. Discovery and Validation Case Studies: Discovery and Development of Multimarker Panels for Improved Prediction of Near-Term Myocardial Infarction. I Horvatovich R, Bischoff R, eds. Comprehensive Biomarker Discovery and Validation for Clinical Application. Cambridge, UK, **Royal Society of Chemistry's Drug Discovery Series** No. 33 2013; p 315-333.
26. Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS, Wiklund O, Hegele RA, Raal FJ, Defesche JC, Wiegman A, Santos RD, Watts GF, Parhofer KG, Hovingh GK, Kovanen PT, Boileau C, Averna M, Borén J, Bruckert E, Catapano AL,

- Kuivenhoven JA, Pajukanta P, Ray K, Stalenhoef AFH, Stroes E, Taskinen M-R, Tybjærg-Hansen A, for the European Atherosclerosis Society Consensus Panel. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease. Consensus statement for the European Atherosclerosis Society. **Eur Heart J** 2013; 34: 3478-3490.
27. Varbo A, Benn M, Nordestgaard BG. Remnant cholesterol as a cause of ischemic heart disease: evidence, definition, measurement, atherogenicity, high risk patients, and present and future treatment. **Pharmacology & Therapeutics** 2014; 141: 358-367.
28. Nordestgaard BG, Lytken Larsen M. Kapitel 28: Hyperlipidæmi. I Schaffalitzky de Muckadell OB, Haunsø S, Vilstrup H, eds. **Medicinsk Kompendium**, 18.ed. København, Nyt Nordisk Forlag Arnold Busck 2013: 828-858.
29. Bojesen SE. Telomeres and human health. **J Intern Med** 2013; 274 :399-413.

#### 2014

30. Hegele R, Ginsberg HN, Chapman MJ, Nordestgaard BG, Kuivenhoven JA, Averna M, Borén J, Bruckert E, Catapano AL, Descamps OS, Hovingh GK, Humphries SE, Kovanen PT, Masana L, Pajukanta P, Parhofer KG, Raal FJ, Ray K, Santos RD, Stalenhoef AFH, Stroes E, Taskinen M-R, Tybjærg-Hansen A, Watts GF, Wiklund O, on behalf of the European Atherosclerosis Society Consensus Panel. The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis and management. **Lancet Diabet Endocrinol** 2014; 2 :655-666.
31. Varbo A, Benn M, Nordestgaard BG. Remnant cholesterol as a cause of ischemic heart disease: evidence, definition, measurement, atherogenicity, high risk patients, and present and future treatment. **Pharmacology & Therapeutics** 2014; 141: 358-367.
32. Varbo A, Nordestgaard BG. Remnant cholesterol and ischemic heart disease. **Curr Opin Lipidol** 2014; 25: 266-273.
33. Nordestgaard BG, Varbo A. Triglycerides and cardiovascular disease. **Lancet** 2014; 384: 626-635.
34. Afzal S, Nordestgaard BG. Low vitamin D and hypertension: a causal association? **Lancet Diabetes Endocrinol** 2014; 2: 682-684.
35. Cuchel M, Bruckert E, Ginsberg HN, Raal FJ, Santos RD, Hegele RA, Kuivenhoven JA, Nordestgaard BG, Descamps OS, Steinhagen-Thiessen E, Tybjærg-Hansen A, Watts GF, Averna M, Boileau C, Borén J, Catapano AL, Defesche JC, Hovingh GK, Humphries SE, Kovanen PT, Masana L, Pajukanta P, Parhofer KG, Ray KK, Stalenhoef AF, Stroes E, Taskinen MR, Wiegman A, Wiklund O, Chapman MJ; for the European Atherosclerosis Society Consensus Panel on Familial Hypercholesterolaemia. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. **Eur Heart J** 2014; 35: 2146-2157.

#### 2015

36. Langsted A, Nordestgaard BG. Nonfasting lipid profiles: the way of the future. **Clin Chem** 2015; 61: 1123-1125.
37. Nordestgaard BG, Langsted A. How does elevated lipoprotein(a) cause aortic valve stenosis? **J Am Coll Cardiol** 2015; 66: 1247-1249.

#### 2016

38. Rifai N, Young I, Nordestgaard BG, Wierzbicki A, Vesper H, Mora S, Stone NJ, Genest J, Miller G. Nonfasting Sample for the Determination of Routine Lipid Profile: Is it an Idea which Time Has Come? **Clin Chem** 2016; 62: 428-435.
39. Nordestgaard BG. Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease: New insights from epidemiology, genetics, and biology. **Circ Res** 2016; 118: 547-563.
40. Nordestgaard BG, Langsted A, Mora S, Kolovou G, Baum H, Bruckert E, Watts GF, Sypniewska G, Wiklund O, Borén J, Chapman MJ, Cobbaert C, Descamps OS, von Eckardstein A, Kamstrup PR, Pulkki K, Kronenberg F, Remaley AT, Rifai N, Ros E, Langlois M, for the European Atherosclerosis Society (EAS) and the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) joint consensus initiative. Fasting is not routinely required for determination of a lipid profile: Clinical and laboratory implications including flagging at desirable concentration cut-points. A joint consensus statement from the EAS and EFLM. **Eur Heart J** 2016; 37: 1944-1958.
41. Nordestgaard BG, Langsted A, Mora S, Kolovou G, Baum H, Bruckert E, Watts GF, Sypniewska G, Wiklund O, Borén J, Chapman MJ, Cobbaert C, Descamps OS, von Eckardstein A, Kamstrup PR, Pulkki K, Kronenberg F, Remaley AT, Rifai N, Ros E, Langlois M, for the European Atherosclerosis Society (EAS) and the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) joint consensus initiative. Fasting is not routinely required for determination of a lipid profile: Clinical and laboratory implications including flagging at desirable concentration cut-points. A joint consensus statement from the EAS and EFLM. **Clin Chem** 2016; 62: 930-946.
42. Kjaergaard AD, Johansen JS, Bojesen SE, Nordestgaard BG. Role of Inflammatory marker YKL-40 in the diagnosis, prognosis, and cause of cardiovascular and liver diseases. **Crit Rev Clin Lab Sci** 2016; 53: 396-408.
43. Varbo A, Langsted A, Nordestgaard BG. Commentary: Nonfasting remnant cholesterol simplifies triglyceride-rich lipoproteins for clinical use, while metabolomic phenotyping ignite scientific curiosity. **Int J Epidemiol** 2016; 45: 1379-1385.
44. Varbo A, Nordestgaard BG. Remnant cholesterol and triglyceride-rich lipoproteins in atherosclerosis progression and cardiovascular disease. **Arterioscler Thromb Vasc Biol** 2016; 36: 2133-2135.
45. Nordestgaard BG, Langsted A. Lipoprotein(a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology. **J Lipid Res** 2016; 57: 1953-1975.
46. Afzal S, Nordestgaard BG. Obesity increases the risk of cardiovascular disease. **Ugeskr Laeger** 2016; 178: 44 p2-6.
47. Nordestgaard BG. *Klinisk Biokemi. Dignostiske fag.* Munksgaard, København 2016.

## 2017

48. Nordestgaard BG. A new start for triglycerides and remnant cholesterol – nonfasting. **Clin Chem** 2017; 63: 1418-1419.
49. Varbo A, Nordestgaard BG. Remnant lipoproteins. **Curr Opin Lipidol** 2017; 28: 300-307.
50. Nordestgaard BG. A Test in Context: Lipid Profile, Fasting versus Non-Fasting. **J Am Coll Cardiol** 2017; 70: 1637-1646.

## 2018

51. Nordestgaard BG, Cosentino F, Landmesser U, Laufs U. The Year in Cardiology 2017: Prevention. **Eur Heart J** 2018; 39: 345-353.
52. Hoogeveen RM, Nahrendorf M, Riksen NP, Netea MG, de Winter MPJ, Lutgens E, Nordestgaard BG, Neidjart M, Stroes ESG, Catapano AL, Bekkering S. Monocyte and

- Haematopoietic Progenitor Reprogramming as Common Mechanism underlying Chronic Inflammatory and Cardiovascular Diseases. **Eur Heart J** 2018; 39: 3521-3527.
53. Nordestgaard BG. Why do the Media report negative news about statins? **Eur Heart J** 2018; 39: 337-338.
54. Benn M, Nordestgaard BG. From genome-wide association studies to Mendelian randomization: Novel opportunities for understanding cardiovascular disease causality, pathogenesis, prevention, and treatment. **Cardiovasc Res** 2018; 114: 1192-1208.
55. Nordestgaard BG, Nicholls SJ, Langsted A, Ray KR, Tybjaerg-Hansen A. Advances in lipid-lowering therapy through gene silencing technologies. **Nat Rev Cardiol** 2018; 15: 261-272.
56. Madsen CM, Nordestgaard BG. Is it time for new thinking about high-density lipoprotein? **Arterioscler Thromb Vasc Biol** 2018; 38: 484-486.
57. Mach F, Ray KK, Wiklund O, Corsini A, Catapano AL, Bruckert E, Backer G, Hegele RA, Hovingh GK, Jacobson TA, Krauss RM, Laufs U, Leiter LA, März W, Nordestgaard BG, Raal FJ, Roden M, Santos RD, Stein EA, Stroes ES, Thompson PD, Tokgözoğlu L, Vladutiu GD, Gencer B, Stock JK, Ginsberg HN, Chapman MJ. Adverse effects of statin therapy: perception versus the evidence. Focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. **Eur Heart J** 2018; 39: 2526-2539.
58. Langlois MR, Chapman MJ, Cobbaert C, Mora S, Remaley AT, Ros E, Watts GF, Borén J, Baum H, Bruckert E, Catapano A, Descamps OS, von Eckardstein A, Kamstrup PR, Kolovou G, Kronenberg F, Langsted A, Pulkki K, Rifai N, Sypniewska G, Wiklund O, Nordestgaard BG for the European Atherosclerosis Society (EAS) and the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) Joint Consensus Initiative. Quantifying Atherogenic Lipoproteins: Current and Future Challenges in the Era of Personalized Medicine and Very Low Concentrations of LDL Cholesterol. A Consensus Statement from EAS and EFLM. **Clin Chem** 2018; 64: 1006-1033.
59. EAS Familial Hypercholesterolaemia Studies Collaboration; EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC) Investigators. Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS familial hypercholesterolaemia Studies Collaboration (FHSC). **Atherosclerosis** 2018; 277: 234-255.

## 2019

60. Langsted A, Nordestgaard BG. Nonfasting versus fasting lipid profile for cardiovascular risk prediction. **Pathology** 2019; 51: 131-141.
61. Varbo A, Nordestgaard BG. Triglycerides or HDL cholesterol in cardiovascular disease – which is the true culprit? **Int J Epidemiol** 2019; online Jan 23.
62. Nordestgaard BG, Mortensen MB. Kapitel 5: Hyperlipidæmi og atherosclerosis. I Schaffalitzky de Muckadell OB, Svendsen JH, Vilstrup H, eds. Medicinsk Kompendium, 19.ed. København, **Munksgaard** 2019: 87-127.
63. Langlois MR, Nordestgaard BG. Which Lipids Should Be Analyzed for Diagnostic Workup and Follow-up of Patients with Hyperlipidemias? **Curr Cardiol Rep** 2018; 20: 88.
64. Kolovou GD, Watts GF, Mikhailidis DP, Pérez-Martínez P, Mora S, Bilianou H, Panotopoulos G, Katsiki N, Ooi TC, Lopez-Miranda J, Tybjaerg-Hansen A, Tentolouris N, Nordestgaard BG. Postprandial Hypertriglyceridaemia Revisited in the Era of Non-fasting Lipid Profiles: Executive Summary of a 2019 Expert Panel Statement. **Curr Vasc Pharmacol** 2019; 17: 538-540.
65. Kolovou GD, Watts GF, Mikhailidis DP, Pérez-Martínez P, Mora S, Bilianou H, Panotopoulos G, Katsiki N, Ooi TC, Lopez-Miranda J, Tybjaerg-Hansen A, Tentolouris N,

- Nordestgaard BG. Postprandial Hypertriglyceridaemia Revisited in the Era of Non-fasting Lipid Profiles: A 2019 Expert Panel Statement, main text. **Curr Vasc Pharmacol** 2019; 17: 498-514.
66. Kolovou GD, Watts GF, Mikhailidis DP, Pérez-Martínez P, Mora S, Bilianou H, Panotopoulos G, Katsiki N, Ooi TC, Lopez-Miranda J, Tybjærg-Hansen A, Tentolouris N, Nordestgaard BG. Postprandial Hypertriglyceridaemia Revisited in the Era of Non-fasting Lipid Profiles: A 2019 Expert Panel Statement, narrative review. **Curr Vasc Pharmacol** 2019; 17: 515-537.
  67. Langsted A, Nordestgaard BG. Antisense oligonucleotides targeting lipoprotein(a). **Curr Atheroscler Rep** 2019; 21: 30.
  68. Fruchart JC, Santos RD, Aguilar-Salinas C, Aikawa M, Al Rasadi K, Amarenco P, Barter PJ, Ceska R, Corsini A, Després JP, Duriez P, Eckel RH, Ezhov MV, Farnier M, Ginsberg HN, Hermans MP, Ishibashi S, Karpe F, Kodama T, Koenig W, Krempf M, Lim S, Lorenzatti AJ, McPherson R, Nuñez-Cortes JM, Nordestgaard BG, Ogawa H, Packard CJ, Plutzky J, Ponte-Negretti CI, Pradhan A, Ray KK, Reiner Ž, Ridker PM, Ruscica M, Sadikot S, Shimano H, Sritara P, Stock JK, Su TC, Susekov AV, Tartar A, Taskinen MR, Tenenbaum A, Tokgözoğlu LS, Tomlinson B, Tybjærg-Hansen A, Valensi P, Vrablík M, Wahli W, Watts GF, Yamashita S, Yokote K, Zambon A, Libby P. The Selective Peroxisome Proliferator-Activated Receptor Alpha Modulator (SPPARM $\alpha$ ) Paradigm: Conceptual Framework and Therapeutic Potential. A Consensus Statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation. **Cardiovasc Diabetol** 2019; 18: 71.
  69. Wilson DP, Jacobson TA, Jones PH, Koschinsky ML, McNeal CJ, Nordestgaard BG, Orringer CE. Use of Lipoprotein(a) in Clinical Practice: A Biomarker Whose Time Has Come. A Scientific Statement from the National Lipid Association. **J Clin Lipidol** 2019; 13: 374-392.
  70. Langsted A, Nordestgaard BG. Lipoprotein(a) should be measured in all individuals suspected of having familial hypercholesterolemia. **Clin Chem** 2019; 65: 1190-1192.
  71. Fruchart JC, Santos RD, Yamashita S, et al; International Atherosclerosis Society/R3i Foundation Consensus Panel. Residual vascular risk in diabetes - Will the SPPARM alpha concept hold the key? **Diabetes Metab Syndr** 2019; 13: 2723-2725.
  72. El-Khoury JM, Remaley AT, Nordestgaard BG, Kaufman HW, Mora S, Cao J, Meusen JW. Perspectives on the Changing Landscape of Measuring Cardiovascular Risk Related to LDL. **Clin Chem** 2019; 65: 1487-1492.

## 2020

73. Representatives of the Global Familial Hypercholesterolemia Community, Wilemon KA, Patel J, Aguilar-Salinas C, Ahmed CD, Alkhnifawi M, Almahmeed W, Alonso R, Al-Rasadi K, Badimon L, Bernal LM, Bogsrud MP, Braun LT, Brunham L, Catapano AL, Čillíková K, Corral P, Cuevas R, Defesche JC, Descamps OS, de Ferranti S, Eiselé J-L, Elikir G, Folco E, Freiburger T, Fuggetta F, Gaspar IM, Gesztes ÁG, Grošelj U, Hamilton-Craig I, Hanauer-Mader G, Harada-Shiba M, Hastings G, Hovingh GK, Izar MC, Jamison A, Karlsson GN, Kayıkçıoğlu M, Koob S, Koseki M, Lane S, Lima-Martinez MM, López G, Martinez TL, Marais D, Marion L, Mata P, Maurina I, Maxwell D, Mehta R, Mensah GA, Miserez AR, Neely D, Nicholls SJ, Nohara A, Nordestgaard BG, Ose L, Pallidis A, Pang J, Payne J, Peterson AL, Popescu MP, Puri R, Ray KK, Reda A, Sampietro T, Santos RD, Schalkers I, Schreier L, Shapiro M, Sijbrands E, Soffer D, Stefanutti C, Stoll M, Sy RG, Tamayo ML, Tilney MK, Tokgözoğlu L, Tomlinson B, Vallejo-Vaz AJ, Vazquez-

- Cárdenas A, de Luca PV, Wald DS, Watts GF, Wenger NK, Wolf M, Wood D, Zegerius A, Gaziano TA, Gidding SS. Reducing the Clinical and Public Health Burden of Familial Hypercholesterolemia. A Global Call to Action. **JAMA Cardiol** 2020; 5: 217-229.
74. Langlois MR, Nordestgaard BG, Langsted A, Chapman MJ, Aakre KM, Baum H, Borén J, Bruckert E, Catapano A, Cobbaert C, Collinson P, Descamps OS, Duff CJ, von Eckardstein A, Hammerer-Lercher A, Kamstrup PR, Kolovou G, Kronenberg F, Mora S, Pulkki K, Remaley AT, Rifai N, Ros E, Stankovic S, Stavljenic-Rukavina A, Sypniewska G, Watts GF, Wiklund O, Laitinen P, for the European Atherosclerosis Society (EAS) and the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) Joint Consensus Initiative. Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM. **Clin Chem Lab Med** 2020; 58: 496-517.
75. Nordestgaard BG, Langlois MR, Langsted A, Chapman MJ, Aakre KM, Baum H, Borén J, Bruckert E, Catapano A, Cobbaert C, Collinson P, Descamps OS, Duff CJ, von Eckardstein A, Hammerer-Lercher A, Kamstrup PR, Kolovou G, Kronenberg F, Mora S, Pulkki K, Remaley AT, Rifai N, Ros E, Stankovic S, Stavljenic-Rukavina A, Sypniewska G, Watts GF, Wiklund O, Laitinen P, for the European Atherosclerosis Society (EAS) and the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) Joint Consensus Initiative. Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM. **Atherosclerosis** 2020; 294:46-61.
76. Borén J, Chapman MJ, Krauss RM, Packard CJ, Bentzon J, Binder CJ, Daemen MJ, Demer LL, Hegele RA, Nicholls SJ, Nordestgaard BG, Watts GF, Bruckert E, Fazio S, Ference BA, Graham I, Horton JD, Landmesser U, Laufs U, Masana L, Pasterkamp G, Raal FJ, Ray KK, Schunkert H, Taskinen M-R, van de Sluis B, Wiklund O, Tokgozoglu L, Catapano AL, Ginsberg HN. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 2. Pathophysiological, genetic and therapeutic insights. A Consensus statement from the European Atherosclerosis Society Consensus Panel. **Eur Heart J** 2020; 41: 2313-2330.
77. Nordestgaard BG, Varbo A. Chapter 8. Triglyceride-rich Lipoprotein Cholesterol (Remnant Cholesterol) as a Therapeutic Target for Cardiovascular Disease Risk. In Michael H. Davidson, Peter P. Toth, Kevin C. Maki, eds. *Therapeutic Lipidology*, 2<sup>nd</sup> ed. Switzerland, **Springer, Humana Press** 2020; p 139-158.
78. Langsted A, Nordestgaard BG. Lipoprotein(a): Is it more, less, or equal to LDL as a causal factor for cardiovascular disease and mortality? **Curr Opin Lipidol** 2020; 31: 125-131.
79. Bruckert E, Parhofer KG, Gonzalez-Juanatey JR, Nordestgaard BG, Arca M, Giovvas P, Ray K K. Proportion of High-Risk/Very High-Risk Patients in Europe with Low-Density Lipoprotein Cholesterol at Target According to European Guidelines: A Systematic Review. **Adv Ther** 2020; 37: 1724-1736.
80. Parhofer KG, Chapman MJ, Nordestgaard BG. Efficacy and Safety of Icosapent Ethyl in Hypertriglyceridaemia – A Recap. **Eur Heart J Suppl** 2020; 22(Suppl J): J21-J33.
- 2021**
81. Apple FS, Daniels L, Mills N, Nordestgaard BG. Biomarkers in Cardiovascular Disease: Utility in Diagnosis, Risk Assessment and Therapy. **Clin Chem** 2021; 67: 1-3.
82. Madsen CM, Varbo A, Nordestgaard BG. Novel insights from human studies on the role of high-density lipoprotein in mortality and noncardiovascular disease. **Arterioscler Thromb**

**Vasc Biol** 2021; 41: 128-140.

83. Meeusen JW, Ueda M, Nordestgaard BG, Remaley AT. Chapter 36. Lipids and Lipoproteins. In Rifai N, Chiu, Young I, Burnham C-AD, Wittwer CT, eds. *Tietz Textbook of Laboratory Medicine*, 7th edition. St. Louis, Missouri, **Elsevier** 2021, in press.
84. Rosenson RS, Koschinsky ML, Nordestgaard BG, Hegele RA. Chapter 10. Hypercholesterolemia, hyperlipoprotein(a), hypertriglyceridemia and low HDL. In Fuster V, Narula J, Vaishnava P, Leon MB, Callans DJ, Rumsfeld JS, eds. *Hurst's The Heart*, 15th edition. New York, **McGraw-Hill** 2021; in press.
85. Langsted A, Nordestgaard BG. Chapter 18. Lipoprotein(a). In Shapiro MD, ed. *Cardiovascular Risk Assessment in Primary Prevention*. **Springer-Nature** 2021; in press.
86. Langsted A, Nordestgaard BG. Genetics of Lipoprotein(a): Cardiovascular Disease and Future Therapy. **Curr Atheroscler Rep** 2021; in press.